environment.uq.edu.au
Feb 23, 2026, 17:42
Bryan Fry: First Evidence That Bothrops atrox Venom Directly Activates Human Factor VII
Bryan Fry, Professor of Toxicology at the University of Queensland, shared a post on LinkedIn, about a recent article he and his colleagues co-authored, adding:
”Highlights
- Neonate Bothrops atrox venom is far more procoagulant than adult venom on plasma and fibrinogen.
- Neonate venom activates prothrombin and Factor VII via FVa-dependent pathways more strongly than adults.
- We provide the first evidence that Bothrops atrox venom directly activates human Factor VII.
- Clinically used antivenoms neutralise adult venom better than neonate venom; Butantan performs best.
- Findings indicate high coagulopathy risk after neonate bites and support adding neonate venom to antivenom immunizing mixture.”
Title: Pirates of the coagulase: Clinical implications of dramatic ontogenetic shifts in Yellow Beard (Bothrops atrox) lancehead pitviper Factor Va-mediated venom activation of blood clotting factors
Authors: Katherine Jordan, Patrick S. Champagne, Lorenzo Seneci, Bryan G. Fry
Read the Full Article on Toxicon.

Stay updated with Hemostasis Today.
-
Feb 23, 2026, 17:34Bastu Odoka: Why Blood Should NOT be Left at the Bedside to ‘Warm’
-
Feb 23, 2026, 17:28Henry Burkitt: Patients Are Challenging How the Medicines Policy System Works in England
-
Feb 23, 2026, 16:50Mutaz Al‑Sabah: Interesting Webinar on FH in Women is Now Available to Watch
-
Feb 23, 2026, 16:36Stéphanie Roullet։ New Method to Explore Primary Haemostasis in Cirrhotic Patients
-
Feb 23, 2026, 16:33Salvatore Massimo Petrina: Top 5 Game-Changers in the AHA and ACC PE Guidelines
-
Feb 23, 2026, 16:21Azin Alizadehasl: Introducing the Second Edition of a New Book on Echocardiography and Cardiac MRI
-
Feb 23, 2026, 16:16Kalyan Roy: When and Why Blood Irradiation Matters in Transfusion Medicine
-
Feb 23, 2026, 15:59Ney Carter Borges: Antithrombotic Therapy in 2025 – A Precision-Based Pharmacologic Update
-
Feb 23, 2026, 15:54Alan Nurden: From Early Discoveries to New Therapeutic Advances in von Willebrand Disease